8-K: Applied DNA Reports Q3 FY25 Results, Focuses on Biotherapeutics

Applied DNA Sciences reported third quarter fiscal 2025 financial results, highlighting a strategic shift to pure-play synthetic DNA and mRNA manufacturing solutions and reduced cash burn.

Summary

• Reported Q3 FY25 financial results for the period ended June 30, 2025.
• The company has transitioned to a pure-play provider of synthetic DNA and mRNA manufacturing solutions through its LineaRx, Inc. subsidiary, following restructuring and workforce reductions.
• The strategic focus is on advanced biotherapeutics (gene therapies, personalized medicine, adoptive cell therapies, mRNA therapeutics, DNA vaccines) and diagnostic applications.
• Introduced LineaDNA, LineaRNAP, and LineaIVT technologies for DNA and mRNA production.
• Monthly net cash burn from operations declined approximately 19% sequentially to $934 thousand and 25% compared to the prior year period.
• Cash and cash equivalents stood at $4.7 million as of June 30, 2025.
• Total revenues from continuing operations were $304 thousand, down from $473 thousand in Q3 FY24.
• Operating loss from continuing operations increased to $3.7 million from $3.3 million in Q3 FY24.
• Adjusted EBITDA from continuing operations was negative $3.9 million, compared to negative $3.2 million in Q3 FY24.
• Received a multi-gram follow-on order for LineaDNA valued at over $600 thousand from a global IVD manufacturer.
• Initiated ISO 13485 certification, expected in Q1 fiscal 2026.
• Effected two reverse stock splits: 1-for-50 on March 14, 2025, and 1-for-15 on June 2, 2025.

Sentiment

Score: 4

Explanation: While the company shows progress in reducing cash burn and securing new orders, the significant decline in revenue and worsening operating loss/Adjusted EBITDA indicate ongoing financial challenges. The strategic pivot is positive, but the financial results are weak, and the multiple reverse stock splits are a strong negative signal.

Positives

• Monthly net cash burn from operations declined approximately 19% sequentially to $934 thousand and 25% compared to the prior year period.
• Expects a further reduction in monthly net cash burn in the quarter ending September 30, 2025.
• Secured a multi-gram follow-on order for LineaDNA valued at over $600 thousand from a global IVD manufacturer for a cancer diagnostic application.
• Added a U.S.-based mRNA contract development manufacturing organization (CDMO) as a customer for LineaDNA IVT templates.
• Launched the LineaRx IVT Discovery Kit, enabling potential customers to easily evaluate its technologies.
• Launched industry marketing for LineaRNAP as a standalone product, confirming higher mRNA yields and integrity with reduced dsRNA.
• Initiated ISO 13485 certification, expected in Q1 fiscal 2026, to enhance customer trust and expand market opportunities.

Negatives

• Total revenues from continuing operations decreased to $304 thousand in Q3 FY25 from $473 thousand in Q3 FY24.
• Operating loss from continuing operations increased to $3.7 million in Q3 FY25 from $3.3 million in Q3 FY24.
• Adjusted EBITDA from continuing operations worsened to negative $3.9 million in Q3 FY25 from negative $3.2 million in Q3 FY24.
• Cash and cash equivalents decreased to $4.7 million as of June 30, 2025, from $5.85 million as of September 30, 2024.
• The company has a history of net losses and limited financial resources.
• Two reverse stock splits (1:50 and 1:15) were effected within the quarter, often indicative of a low share price and potential delisting concerns.

Risks

• History of net losses.
• Limited financial resources.
• Unknown future ability to remain compliant with all Nasdaq listing standards.
• Unknown future demand for biotherapeutics products and services.
• Unknown amount of revenues and profits that will result from its technologies.
• No therapeutic clinical trial material and/or a commercial drug product has ever been produced utilizing its technologies.
• Uncertainty whether its restructuring will position the Company for future growth potential.

Future Outlook

The company expects a further reduction in monthly net cash burn from operations in the quarter ending September 30, 2025, reflecting the implementation of Corporate Actions. It aims to position itself for long-term growth and value creation through its focused biotherapeutics strategy and expects to achieve ISO 13485 certification in the first quarter of fiscal 2026.

Management Comments

• "Our operational activities center on repositioning Applied DNA as a single business that is aligned with our proven core competencies, which underpin our commercially available, cell-free DNA and mRNA manufacturing solutions offerings."
• "With operations now right-sized, coupled with active marketing under the LineaRx brand that is now synonymous with synthetically produced DNA, we look forward to delivering value to shareholders."

Industry Context

Applied DNA Sciences' strategic pivot to focus solely on synthetic DNA and mRNA manufacturing solutions aligns with the rapidly expanding biotherapeutics market, driven by advancements in gene therapies, personalized medicine, and mRNA vaccines. The company's LineaDNA, LineaRNAP, and LineaIVT platforms aim to address critical production bottlenecks and quality concerns (e.g., dsRNA contamination) in this high-growth sector. This specialization positions the company to capitalize on the increasing demand for high-fidelity nucleic acid components, a trend observed across the biopharmaceutical and diagnostics industries.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from strategic pivot, but current financial losses and reverse stock splits indicate significant dilution and value erosion. Cash burn reduction is a positive.
• Employees: Workforce reductions have already occurred as part of Corporate Actions.
• Customers: New customer acquisitions and follow-on orders indicate growing adoption of LineaRx technologies. ISO 13485 certification aims to enhance trust.
• Creditors: Limited financial resources and history of net losses could pose risks.

Next Steps

• Further reduce monthly net cash burn from operations in the quarter ending September 30, 2025.
• Continue active marketing under the LineaRx brand.
• Complete ISO 13485 certification in the first quarter of fiscal 2026.
• Engage potential customers and showcase platform capabilities at mRNA-focused conferences.
• Follow up on sales quotes provided to large public biotech and multinational biotech tools companies for LineaDNA.

Key Dates

Recommendation

Despite a strategic pivot towards a high-growth biotherapeutics market and a commendable reduction in cash burn, the company's Q3 FY25 financial results show a significant year-over-year decline in revenue and worsening operating losses and Adjusted EBITDA. The history of net losses, limited financial resources, and the execution of two substantial reverse stock splits within the quarter signal severe financial distress and significant shareholder dilution. While new customer acquisitions and product development are positive, the company faces substantial risks, including unknown future demand and the lack of a commercial drug product utilizing its technologies. The current financial performance and ongoing capital needs suggest a high-risk investment profile, warranting a 'sell' recommendation for seasoned investors.

Keywords

Applied DNA Sciences, APDN, LineaRx, synthetic DNA, mRNA manufacturing, biotherapeutics, gene therapy, personalized medicine, adoptive cell therapy, DNA vaccines, diagnostics, LineaDNA, LineaRNAP, LineaIVT, cell-free DNA, PCR, T7 RNA polymerase, biotechnology, financial results, cash burn, ISO 13485, reverse stock split